Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies*

Kabashima, Kenji; Matsumura, Takayo; Komazaki, Hiroshi; Kawashima, Makoto

doi:10.1111/bjd.20873

Cited by 58 publications

(43 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nemolizumab significantly reduces the itch, as well as AD severity compared to placebo [ 55 ]. Moreover, the results from two phase III long-term studies in patients with atopic dermatitis have confirmed that the use of nemolizumab with topical treatments produces even greater, continuous improvement in pruritus, signs of the disease, and patients’ QoL [ 56 ]. Similar findings were observed in the treatment of chronic prurigo.…”

Section: Discussionmentioning

confidence: 99%

High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients

Krajewski

Tyczyńska

Bardowska

et al. 2022

JCM

View full text Add to dashboard Cite

Chronic itch (CI) is a common symptom caused by both dermatological and systemic disorders. CI is also a frequent, burdensome symptom among renal transplant recipients (RTR); however, its pathophysiology is not fully understood. The aim of this study was to assess the differences in concentration of IL-31 among itchy RTR. The study was performed on a group of selected 129 RTRs (54 itchy and 75 non-itchy patients). Itch severity was assessed with the use of the numeral rating scale (NRS) and the 4-item itch questionnaire (4IIQ). Every subject had his blood drawn to measure the concentration of IL-31. The results were subsequently compared and correlated. The mean concentration differed significantly between RTR suffering from itch (602.44 ± 534.5 pg/mL), non-itchy RTR (161.49 ± 106.61 pg/mL), and HC (110.33 ± 51.81 pg/mL) (p < 0.001). Post-hoc analysis revealed a statistically significantly increased IL-31 serum concentration in itchy RTR in comparison to the non-itchy RTR group (p < 0.001) and HC (p < 0.001). No significant difference was observed in IL-31 serum levels between non-itchy RTRs and HC. No correlation between IL-31 and itch intensity was found. The results of our study clearly demonstrate the association between IL-31 levels and CI in patients after renal transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients

Krajewski

Tyczyńska

Bardowska

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…dupilumab, tralokinumab, lebrikizumab and nemolizumab). 40 – 47 Whether and how these cytokines affect the complex and inter-dependent epidermal structures that result in a healthy barrier is still being studied.…”

Section: Historical Perspective On Ad Skin Barrier Defectsmentioning

confidence: 99%

Skin barrier defects in atopic dermatitis: From old idea to new opportunity

Yoshida

Beck

Benedetto

2022

Allergology International

View full text Add to dashboard Cite

“…The H4R antagonist adriforant slightly improved disease severity without statistically significant effects on pruritus in a phase IIa study [ 49 ], and further programs for H4R antagonists for AD have been suspended [ 3 , 49 ]. The anti-IL-31 ab nemolizumab significantly reduced pruritus in AD and prurigo nodularis [ 50 , 51 ]. IL-31 is produced by several T2 cells such as Th2 cells, mast cells, macrophages, and dendritic cells, activates neurons via IL-31Rα, TRPV1 or TRPA1, and further induces the recruitment of T cells by chemotactic cytokines along with increases of neuronal branching in the skin in a vicious cycle [ 3 , 36 , 52 ].…”

Section: Evidence That Skin Barrier Dysfunction Is a Key Precursor Of Admentioning

confidence: 99%

From Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine

Maintz

Bieber

Simpson³

et al. 2022

JPM

View full text Add to dashboard Cite

: Atopic dermatitis (AD) affects up to 20% of children and is considered the starting point of the atopic march with the development of food allergy, asthma, and allergic rhinitis. The heterogeneous phenotype reflects distinct and/or overlapping pathogenetic mechanisms with varying degrees of epidermal barrier disruption, activation of different T cell subsets and dysbiosis of the skin microbiome. Here, we review current evidence suggesting a systemic impact of the cutaneous inflammation in AD together with a higher risk of asthma and other comorbidities, especially in severe and persistent AD. Thus, early therapy of AD to restore the impaired skin barrier, modified microbiome, and target type 2 inflammation, depending on the (endo)phenotype, in a tailored approach is crucial. We discuss what we can learn from the comorbidities and the implications for preventive and therapeutic interventions from precision dermocosmetics to precision medicine. The stratification of AD patients into biomarker-based endotypes for a precision medicine approach offers opportunities for better long-term control of AD with the potential to reduce the systemic impact of a chronic skin inflammation and even prevent or modify the course, not only of AD, but possibly also the comorbidities, depending on the patient’s age and disease stage.

show abstract

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies*

Abstract: The trial sponsor was involved in the study design, the collection, analysis, interpretation of data, and the decision to submit the article for publication. Maruho also paid for professional writing assistance. Nemolizumab and placebo were provided by the product manufacturer,

Cited by 58 publications

References 43 publications

High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients

High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients

Skin barrier defects in atopic dermatitis: From old idea to new opportunity

From Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine

Contact Info

Product

Resources

About